Skip to main content
Top
Published in: Digestive Diseases and Sciences 1/2016

01-01-2016 | Original Article

Yield of Repeat Endoscopy in Barrett’s Esophagus with No Dysplasia and Low-Grade Dysplasia: A Population-Based Study

Authors: Kavel Visrodia, Prasad G. Iyer, Cathy D. Schleck, Alan R. Zinsmeister, David A. Katzka

Published in: Digestive Diseases and Sciences | Issue 1/2016

Login to get access

Abstract

Background

The yield of early repeat endoscopy in patients with Barrett’s esophagus (BE) is not well established.

Aims

To determine how often early repeat endoscopy detected missed dysplasia or esophageal adenocarcinoma (EAC) in a population-based cohort of patients with BE. Secondary aims were to identify risk factors for missed dysplasia/EAC and compare detection of prevalent versus incident HGD/EAC.

Methods

A population-based cohort of BE subjects in Olmsted County, MN, was studied. Patients with initial non-dysplastic BE or low-grade dysplasia (LGD) who underwent repeat endoscopy within 24 months were included. Those with a worse histologic diagnosis on repeat endoscopy were considered to have missed dysplasia/EAC. Baseline characteristics among patients with and without missed dysplasia/EAC were compared. The absolute numbers of asymptomatic prevalent or missed, and incident HGD/EAC in the entire cohort were ascertained.

Results

Of 488 BE cases, 210 were included for the primary aim of this study. Repeat endoscopy revealed four HGD/EAC (1.9 %) and 16 LGD (8.8 %) for a combined miss rate of 9.5 %. Long-segment BE (LSBE) and lack of PPI use were predictors of missed dysplasia/EAC (P = 0.008), but adherence to biopsy protocol was not. Increased prevalent HGD/EAC (n = 30) rather than incident HGD/EAC (n = 22) was identified during a median 4.8 years of follow-up in this cohort.

Conclusions

Dysplasia/EAC is commonly missed at initial BE diagnosis, particularly in patients with LSBE and no PPI use. Efforts should be made to enhance the sensitivity of detecting dysplasia/neoplasia around the time of initial BE diagnosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett’s esophagus: the aga chicago workshop. Gastroenterology. 2004;127:310–330.CrossRefPubMed Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett’s esophagus: the aga chicago workshop. Gastroenterology. 2004;127:310–330.CrossRefPubMed
2.
go back to reference Abrams JA, Kapel RC, Lindberg GM, et al. Adherence to biopsy guidelines for Barrett’s esophagus surveillance in the community setting in the United States. Clin Gastroenterol Hepatol. 2009;7:736–742. quiz 710.PubMedCentralCrossRefPubMed Abrams JA, Kapel RC, Lindberg GM, et al. Adherence to biopsy guidelines for Barrett’s esophagus surveillance in the community setting in the United States. Clin Gastroenterol Hepatol. 2009;7:736–742. quiz 710.PubMedCentralCrossRefPubMed
3.
go back to reference Curvers WL, Peters FP, Elzer B, et al. Quality of Barrett’s surveillance in the Netherlands: a standardized review of endoscopy and pathology reports. Eur J Gastroenterol Hepatol. 2008;20:601–607.CrossRefPubMed Curvers WL, Peters FP, Elzer B, et al. Quality of Barrett’s surveillance in the Netherlands: a standardized review of endoscopy and pathology reports. Eur J Gastroenterol Hepatol. 2008;20:601–607.CrossRefPubMed
4.
go back to reference Chatelain D, Flejou JF. High-grade dysplasia and superficial adenocarcinoma in Barrett’s esophagus: histological mapping and expression of p53, p21 and bcl-2 oncoproteins. Virchows Archiv. 2003;442:18–24.PubMed Chatelain D, Flejou JF. High-grade dysplasia and superficial adenocarcinoma in Barrett’s esophagus: histological mapping and expression of p53, p21 and bcl-2 oncoproteins. Virchows Archiv. 2003;442:18–24.PubMed
5.
go back to reference McArdle JE, Lewin KJ, Randall G, Weinstein W. Distribution of dysplasias and early invasive carcinoma in Barrett’s esophagus. Hum Pathol. 1992;23:479–482.CrossRefPubMed McArdle JE, Lewin KJ, Randall G, Weinstein W. Distribution of dysplasias and early invasive carcinoma in Barrett’s esophagus. Hum Pathol. 1992;23:479–482.CrossRefPubMed
6.
go back to reference Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American gastroenterological association technical review on the management of Barrett’s esophagus. Gastroenterology. 2011;140:e18–e52. quiz e13.PubMedCentralCrossRefPubMed Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American gastroenterological association technical review on the management of Barrett’s esophagus. Gastroenterology. 2011;140:e18–e52. quiz e13.PubMedCentralCrossRefPubMed
7.
go back to reference Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol. 2008;103:788–797.CrossRefPubMed Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol. 2008;103:788–797.CrossRefPubMed
8.
go back to reference Evans JA, Early DS, Fukami N, et al. The role of endoscopy in Barrett’s esophagus and other premalignant conditions of the esophagus. Gastrointest Endosc. 2012;76:1087–1094.CrossRefPubMed Evans JA, Early DS, Fukami N, et al. The role of endoscopy in Barrett’s esophagus and other premalignant conditions of the esophagus. Gastrointest Endosc. 2012;76:1087–1094.CrossRefPubMed
9.
go back to reference Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett’s esophagus. The practice parameters committee of the American college of gastroenterology. Am J Gastroenterol. 1998;93:1028–1032.CrossRefPubMed Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett’s esophagus. The practice parameters committee of the American college of gastroenterology. Am J Gastroenterol. 1998;93:1028–1032.CrossRefPubMed
10.
go back to reference Jung KW, Talley NJ, Romero Y, et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett’s esophagus: a population-based study. Am J Gastroenterol. 2011;106:1447–1455. quiz 1456.PubMedCentralCrossRefPubMed Jung KW, Talley NJ, Romero Y, et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett’s esophagus: a population-based study. Am J Gastroenterol. 2011;106:1447–1455. quiz 1456.PubMedCentralCrossRefPubMed
11.
go back to reference Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001;32:368–378.CrossRefPubMed Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001;32:368–378.CrossRefPubMed
12.
go back to reference Rastogi A, Puli S, El-Serag HB, Bansal A, Wani S, Sharma P. Incidence of esophageal adenocarcinoma in patients with Barrett’s esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc. 2008;67:394–398.CrossRefPubMed Rastogi A, Puli S, El-Serag HB, Bansal A, Wani S, Sharma P. Incidence of esophageal adenocarcinoma in patients with Barrett’s esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc. 2008;67:394–398.CrossRefPubMed
13.
go back to reference Wani S, Falk GW, Post J, et al. Risk factors for progression of low-grade dysplasia in patients with Barrett’s esophagus. Gastroenterology. 2011;141:1179–1186, 1186 e1171. Wani S, Falk GW, Post J, et al. Risk factors for progression of low-grade dysplasia in patients with Barrett’s esophagus. Gastroenterology. 2011;141:1179–1186, 1186 e1171.
14.
go back to reference Verbeek RE, Leenders M, Ten Kate FJ, et al. Surveillance of Barrett’s esophagus and mortality from esophageal adenocarcinoma: a population-based cohort study. Am J Gastroenterol. 2014;109:1215–1222.CrossRefPubMed Verbeek RE, Leenders M, Ten Kate FJ, et al. Surveillance of Barrett’s esophagus and mortality from esophageal adenocarcinoma: a population-based cohort study. Am J Gastroenterol. 2014;109:1215–1222.CrossRefPubMed
15.
go back to reference Singh S, Manickam P, Amin AV, et al. Incidence of esophageal adenocarcinoma in Barrett’s esophagus with low-grade dysplasia: a systematic review and meta-analysis. Gastrointest Endosc. 2014;79:897–909. e894.CrossRefPubMed Singh S, Manickam P, Amin AV, et al. Incidence of esophageal adenocarcinoma in Barrett’s esophagus with low-grade dysplasia: a systematic review and meta-analysis. Gastrointest Endosc. 2014;79:897–909. e894.CrossRefPubMed
16.
go back to reference Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE. Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2006;4:566–572.CrossRefPubMed Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE. Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2006;4:566–572.CrossRefPubMed
17.
go back to reference Curvers WL, ten Kate FJ, Krishnadath KK, et al. Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010;105:1523–1530.CrossRefPubMed Curvers WL, ten Kate FJ, Krishnadath KK, et al. Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010;105:1523–1530.CrossRefPubMed
18.
go back to reference Abdalla M, Dhanekula R, Greenspan M, et al. Dysplasia detection rate of confirmatory egd in nondysplastic Barrett’s esophagus. Dis Esophagus. 2014;27:505–510.CrossRefPubMed Abdalla M, Dhanekula R, Greenspan M, et al. Dysplasia detection rate of confirmatory egd in nondysplastic Barrett’s esophagus. Dis Esophagus. 2014;27:505–510.CrossRefPubMed
19.
go back to reference Kariv R, Plesec TP, Goldblum JR, et al. The Seattle protocol does not more reliably predict the detection of cancer at the time of esophagectomy than a less intensive surveillance protocol. Clin Gastroenterol Hepatol. 2009;7:653–658; quiz 606. Kariv R, Plesec TP, Goldblum JR, et al. The Seattle protocol does not more reliably predict the detection of cancer at the time of esophagectomy than a less intensive surveillance protocol. Clin Gastroenterol Hepatol. 2009;7:653–658; quiz 606.
20.
go back to reference Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365:1375–1383.CrossRefPubMed Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365:1375–1383.CrossRefPubMed
21.
go back to reference Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103:1049–1057.PubMedCentralCrossRefPubMed Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103:1049–1057.PubMedCentralCrossRefPubMed
22.
go back to reference Thomas T, Abrams KR, De Caestecker JS, Robinson RJ. Meta analysis: cancer risk in Barrett’s oesophagus. Aliment Pharmacol Therap. 2007;26:1465–1477.CrossRef Thomas T, Abrams KR, De Caestecker JS, Robinson RJ. Meta analysis: cancer risk in Barrett’s oesophagus. Aliment Pharmacol Therap. 2007;26:1465–1477.CrossRef
23.
go back to reference Corley DA, Mehtani K, Quesenberry C, Zhao W, de Boer J, Weiss NS. Impact of endoscopic surveillance on mortality from Barrett’s esophagus-associated esophageal adenocarcinomas. Gastroenterology. 2013;145:312–319. e311.PubMedCentralCrossRefPubMed Corley DA, Mehtani K, Quesenberry C, Zhao W, de Boer J, Weiss NS. Impact of endoscopic surveillance on mortality from Barrett’s esophagus-associated esophageal adenocarcinomas. Gastroenterology. 2013;145:312–319. e311.PubMedCentralCrossRefPubMed
24.
go back to reference Armstrong D. Should patients with Barrett’s oesophagus be kept under surveillance? The case for. Best Pract Res Clin Gastroenterol. 2008;22:721–739.CrossRefPubMed Armstrong D. Should patients with Barrett’s oesophagus be kept under surveillance? The case for. Best Pract Res Clin Gastroenterol. 2008;22:721–739.CrossRefPubMed
25.
go back to reference Barritt AS, Shaheen N. Should patients with Barrett’s oesophagus be kept under surveillance? The case against. Best Pract Res Clin Gastroenterol. 2008;22:741–750.CrossRefPubMed Barritt AS, Shaheen N. Should patients with Barrett’s oesophagus be kept under surveillance? The case against. Best Pract Res Clin Gastroenterol. 2008;22:741–750.CrossRefPubMed
26.
go back to reference Moayyedi P, Burch N, Akhtar-Danesh N, et al. Mortality rates in patients with Barrett’s oesophagus. Aliment Pharmacol Ther. 2008;27:316–320.CrossRefPubMed Moayyedi P, Burch N, Akhtar-Danesh N, et al. Mortality rates in patients with Barrett’s oesophagus. Aliment Pharmacol Ther. 2008;27:316–320.CrossRefPubMed
27.
go back to reference Gupta N, Gaddam S, Wani SB, Bansal A, Rastogi A, Sharma P. Longer inspection time is associated with increased detection of high-grade dysplasia and esophageal adenocarcinoma in Barrett’s esophagus. Gastrointest Endosc. 2012;76:531–538.CrossRefPubMed Gupta N, Gaddam S, Wani SB, Bansal A, Rastogi A, Sharma P. Longer inspection time is associated with increased detection of high-grade dysplasia and esophageal adenocarcinoma in Barrett’s esophagus. Gastrointest Endosc. 2012;76:531–538.CrossRefPubMed
Metadata
Title
Yield of Repeat Endoscopy in Barrett’s Esophagus with No Dysplasia and Low-Grade Dysplasia: A Population-Based Study
Authors
Kavel Visrodia
Prasad G. Iyer
Cathy D. Schleck
Alan R. Zinsmeister
David A. Katzka
Publication date
01-01-2016
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 1/2016
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-015-3697-6

Other articles of this Issue 1/2016

Digestive Diseases and Sciences 1/2016 Go to the issue